Pharming Group N.V [PHAR] vs Travere Therapeutics [TVTX] Detailed Stock Comparison
Pharming Group N.V
NASDAQ
Loading...
Travere Therapeutics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Pharming Group N.V wins in 13 metrics, Travere Therapeutics wins in 4 metrics, with 0 ties. Pharming Group N.V appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Pharming Group N.V | Travere Therapeutics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 69.31 | -6.69 | Travere Therapeutics |
| Price-to-Book Ratio | 38.60 | 74.21 | Pharming Group N.V |
| Debt-to-Equity Ratio | 53.57 | 1,220.18 | Pharming Group N.V |
| PEG Ratio | N/A | 0.08 | N/A |
| EV/EBITDA | 386.44 | -20.86 | Travere Therapeutics |
| Profit Margin (TTM) | -2.41% | -50.64% | Pharming Group N.V |
| Operating Margin (TTM) | 3.27% | -11.05% | Pharming Group N.V |
| EBITDA Margin (TTM) | 3.27% | N/A | N/A |
| Return on Equity | -3.70% | -705.73% | Pharming Group N.V |
| Return on Assets (TTM) | 2.85% | -19.28% | Pharming Group N.V |
| Free Cash Flow (TTM) | $-2.59M | $-338.69M | Pharming Group N.V |
| 1-Year Return | 95.73% | 74.11% | Pharming Group N.V |
| Price-to-Sales Ratio (TTM) | 2.72 | 7.29 | Pharming Group N.V |
| Enterprise Value | $10.19B | $2.51B | Pharming Group N.V |
| EV/Revenue Ratio | 29.99 | 7.53 | Travere Therapeutics |
| Gross Profit Margin (TTM) | 90.38% | 98.67% | Travere Therapeutics |
| Revenue per Share (TTM) | $5 | $4 | Pharming Group N.V |
| Earnings per Share (Diluted) | $-0.14 | $-2.02 | Pharming Group N.V |
| Beta (Stock Volatility) | 0.59 | 0.79 | Pharming Group N.V |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Pharming Group N.V vs Travere Therapeutics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Pharming Group N.V | -0.81% | -3.80% | 29.91% | 26.99% | 89.66% | 40.34% |
| Travere Therapeutics | -6.12% | 8.46% | 34.81% | 57.10% | 21.80% | 23.72% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Pharming Group N.V | 95.73% | 31.54% | -5.84% | -5.84% | -5.84% | -5.84% |
| Travere Therapeutics | 74.11% | -11.67% | 15.90% | -17.85% | 1,067.66% | 1,067.66% |
News Based Sentiment: Pharming Group N.V vs Travere Therapeutics
Pharming Group N.V
News based Sentiment: POSITIVE
Pharming Group delivered strong Q2 results, raised guidance, and continues to attract institutional investment. While recent trading has shown some volatility, the overall narrative is positive, driven by revenue growth and a positive analyst outlook. The appointment of a new CFO adds another layer to the story.
Travere Therapeutics
News based Sentiment: POSITIVE
The month of September was marked by a significant increase in institutional investment in Travere Therapeutics, alongside positive analyst sentiment and continued progress in its pipeline. While some insider selling occurred, it was explained as tax-related, and the overall narrative suggests growing confidence in the company's prospects, particularly with the success of FILSPARI and upcoming FDA decisions.
Performance & Financial Health Analysis: Pharming Group N.V vs Travere Therapeutics
| Metric | PHAR | TVTX |
|---|---|---|
| Market Information | ||
| Market Cap | $953.47M | $2.43B |
| Market Cap Category | Small cap | Mid cap |
| 10 Day Avg. Volume | 9,864 | 3,513,850 |
| 90 Day Avg. Volume | 12,955 | 2,229,163 |
| Last Close | $14.68 | $23.47 |
| 52 Week Range | $7.10 - $17.08 | $11.89 - $28.69 |
| % from 52W High | -14.05% | -18.20% |
| All-Time High | $21.99 (Dec 21, 2020) | $37.04 (Aug 03, 2015) |
| % from All-Time High | -33.24% | -36.64% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.26% | 1.12% |
| Quarterly Earnings Growth | 0.26% | 1.11% |
| Financial Health | ||
| Profit Margin (TTM) | -0.02% | -0.51% |
| Operating Margin (TTM) | 0.03% | -0.11% |
| Return on Equity (TTM) | -0.04% | -7.06% |
| Debt to Equity (MRQ) | 53.57 | 1,220.18 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.35 | $0.37 |
| Cash per Share (MRQ) | $0.18 | $3.59 |
| Operating Cash Flow (TTM) | $31.05M | $-115,438,000 |
| Levered Free Cash Flow (TTM) | $23.18M | $-81,794,376 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Pharming Group N.V vs Travere Therapeutics
| Metric | PHAR | TVTX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 69.31 | -6.69 |
| Forward P/E | 293.70 | -22.39 |
| PEG Ratio | N/A | 0.08 |
| Price to Sales (TTM) | 2.72 | 7.29 |
| Price to Book (MRQ) | 38.60 | 74.21 |
| Market Capitalization | ||
| Market Capitalization | $953.47M | $2.43B |
| Enterprise Value | $10.19B | $2.51B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 29.99 | 7.53 |
| Enterprise to EBITDA | 386.44 | -20.86 |
| Risk & Other Metrics | ||
| Beta | 0.59 | 0.79 |
| Book Value per Share (MRQ) | $0.35 | $0.37 |
Financial Statements Comparison: Pharming Group N.V vs Travere Therapeutics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PHAR | TVTX |
|---|---|---|
| Revenue/Sales | $93.22M | $81.73M |
| Cost of Goods Sold | $8.97M | $4.68M |
| Gross Profit | $84.25M | $77.05M |
| Research & Development | $23.70M | $46.89M |
| Operating Income (EBIT) | $9.00M | $-42.67M |
| EBITDA | $9.79M | $-25.53M |
| Pre-Tax Income | $7.08M | $-41.19M |
| Income Tax | $2.53M | $39,000 |
| Net Income (Profit) | $4.55M | $-41.23M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PHAR | TVTX |
|---|---|---|
| Cash & Equivalents | $60.09M | $61.90M |
| Total Current Assets | $214.11M | $374.17M |
| Total Current Liabilities | $77.54M | $182.46M |
| Long-Term Debt | $110.36M | $326.25M |
| Total Shareholders Equity | $215.29M | $32.82M |
| Retained Earnings | $-292.80M | $-1.49B |
| Property, Plant & Equipment | $24.23M | $4.85M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PHAR | TVTX |
|---|---|---|
| Operating Cash Flow | $2.07M | $-30.99M |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | $-56,000 | $-53.98M |
| Debt Repayment | $-715,000 | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PHAR | TVTX |
|---|---|---|
| Shares Short | 1,414 | 12.08M |
| Short Ratio | 0.14 | 7.46 |
| Short % of Float | 0.00% | 0.14% |
| Average Daily Volume (10 Day) | 9,864 | 3,513,850 |
| Average Daily Volume (90 Day) | 12,955 | 2,229,163 |
| Shares Outstanding | 680.31M | 87.45M |
| Float Shares | 670.71M | 79.29M |
| % Held by Insiders | 0.00% | 0.01% |
| % Held by Institutions | 0.00% | 1.17% |
Dividend Analysis & Yield Comparison: Pharming Group N.V vs Travere Therapeutics
| Metric | PHAR | TVTX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |